Aro Biotherapeutics to Highlight Therapeutic Potential of Centyrin Oligonucleotide Conjugates at Upcoming Industry Conferences

Aro Biotherapeutics to Highlight Therapeutic Potential of Centyrin Oligonucleotide Conjugates at Upcoming Industry Conferences




Aro Biotherapeutics to Highlight Therapeutic Potential of Centyrin Oligonucleotide Conjugates at Upcoming Industry Conferences

Company to Present New Data Demonstrating Centyrin Oligonucleotide Conjugates Achieve Potent and Tissue-Specific Gene Knockdown

​ PHILADELPHIA–(BUSINESS WIRE)–Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced upcoming data presentations highlighting the therapeutic potential of its proprietary Centyrin oligonucleotide conjugate therapies. The presentations will take place at the 2022 European Laboratory Research & Innovation Group (ELRIG) Research & Innovation Conference, the 3rd Annual RNAi – Based Therapeutics Summit, and TIDES USA.

In the upcoming presentations, Aro scientists will present new in vivo proof-of-concept data demonstrating advantages of its Centyrin – oligonucleotide platform for achieving potent and specific inhibition of disease-causing mRNAs and proteins in selected disease relevant tissues. Furthermore, the presentations will highlight the modularity of the platform for tissue targeting of both siRNA and antisense oligonucleotides conjugated to receptor specific Centyrins. In addition, Aro will present original data on Centyrin-siRNA conjugates in animal models of Pompe disease, demonstrating that the platform holds great promise for addressing unmet needs in this rare disease population.

Our team looks forward to sharing the scientific data that validates the broad potential of Centyrin-oligonucleotide conjugates to address genetic diseases with high unmet medical needs,” said Susan Dillon, Ph.D., co-founder and Chief Executive Officer of Aro Biotherapeutics. “Aro’s drug discovery platform is designed to discover and optimize receptor-specific Centyrin-siRNA conjugates that achieve precise in vivo modulation of gene targets at the site of disease – addressing one of the greatest challenges facing genetic medicines today.”

Following are additional details about the conferences and presentations:

2022 ELRIG Research & Innovation Conference

Session:
Creating a New Class of Centyrin – Oligonucleotide Therapeutics

Presenter: Sukumar Sakamuri, Ph.D., Chief Technology Officer

Date: March 30, 2022

3rd Annual RNAi – Based Therapeutics Summit

Session:
Creating a New Class of Receptor-Targeting Genetic Medicine

Presenter: Zhanna Druzina, Ph.D., Senior Director, Protein Engineering

Date: April 19, 2022

TIDES USA

Session:
Centyrin-targeted siRNA Conjugates Demonstrate Potential New Therapeutic Approach for Reduction of Skeletal Muscle Glycogen in Pompe Disease

Presenter: Karyn O’Neil, Ph.D., Chief Scientific Officer

Date: May 11, 2022

About Aro Biotherapeutics

Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases. For more information, visit www.arobiotx.com.

Contacts

Mike Beyer

Sam Brown Inc.

mikebeyer@sambrown.com
312-961-2502